Nonoxinol - 9
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
Vaginal gel containing 2% w/w nonoxinol-9.
Vaginal cream containing 2% w/w nonoxinol-9.
For use as a spermicidal contraceptive in conjunction with barrier methods of contraception.
Use and instructions vary between brands:
Apply not more than 3 hours before sexual intercourse.
Spread the preparation over the surface of the diaphragm / cap that will be in contact with the cervix and on the rim. Re-apply prior to any subsequent act of sexual intercourse using the vaginal applicator without removing the diaphragm / cap.
Leave diaphragm /cap in place for at least 6 - 8 hours after coitus. Do not leave in place for longer than 24 hours.
For vaginal use only.
Patients with absent vaginal sensation (e.g. paraplegics and quadriplegics)
Children under 18 years
Precautions and Warnings
Spermicidal contraceptives are useful additional safeguards when used in conjunction with barrier methods of contraception such as condoms, diaphragms and caps, but are not a totally reliable form of contraception.
The preparation should be applied or re-applied not more than 3 hours before intercourse and between repeated acts of sexual intercourse (see adult dosage).
The diaphragm /cap must be left in place for 6 - 8 hours post coitus, but not for longer than 24 hours (see adult dosage).
Advise patient to avoid douching for at least 6 hours after intercourse.
Intravaginal spermicidal contraceptive preparations do not protect against HIV or other sexually transmitted diseases. Frequent use may cause epithelial damage and increase the risk of HIV infection. Women at risk of HIV or other sexually transmitted diseases or who have multiple daily acts of intercourse should be advised to use a different form of contraception.
Advise patient that if vaginal or penile irritation occurs, they should discontinue use and if symptoms worsen or continue for more than 48 hours, they should seek medical advice.
CSM WarningsProducts such as petroleum jelly, baby-oil and oil based vaginal and rectal preparations are likely to damage condoms and contraceptive diaphragms made from latex rubber, and may render them less effective as a barrier method of contraception and as a protection from sexually transmitted diseases (including HIV).
Pregnancy and Lactation
Contraindicated during pregnancy.
There is no evidence of nonoxinol - 9 being teratogenic. Human epidemiological studies have shown no evidence of foetotoxicity. However some animal studies have shown evidence of embryotoxicity.
Contraindicated in lactation.
Human studies have not been carried out in lactating women and animal studies have detected nonoxinol-9 milk after intravaginal administration.
Effects on Ability to Drive and Operate Machinery
Advise patient to discontinue use if vaginal or penile irritation occurs and to seek medical attention if these symptoms deteriorate or persist for more than 48 hours.
Advise patient that spermicidal contraceptives are useful additional safeguards when used in conjunction with barrier methods of contraception such as condoms, diaphragms and caps, but are not a totally reliable form of contraception.
Advise patient that intravaginal spermicidal contraceptive preparations do not protect against HIV or other sexually transmitted diseases and frequent use may cause epithelial damage and increase the risk of HIV infection. Therefore women at risk of HIV or other sexually transmitted diseases or who have multiple daily acts of intercourse should be advised to use a different form of contraception.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet (https://www.toxbase.org/).
Shelf Life and Storage
Do not store above 25 degrees C
Do not freeze
Storage requirements may vary between brands.
Summary of Product characteristics for Gygel contraceptive jelly from Marlborough Pharmaceuticals Ltd dated July 2007
Summary of Product Characteristics Gynol II contraceptive jelly. Janssen-Cilag Ltd, 23rd October 2002.
Summary of Product Characteristics Ortho-Creme contraceptive cream. Janssen-Cilag Ltd, 23rd October 2002.
Summary of Product Characteristics Duragel. SSL International plc, March 1998.
BNF (54) September 2007
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.